MARKERS OF SEVERITY IN CHRONIC SYSTEMIC DISEASES: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.56238/levv17n56-016Keywords:
Chronic Disease, Severity of Illness Index, Biomarkers, PrognosisAbstract
Introduction: Chronic systemic diseases represent a major cause of morbidity and mortality worldwide, and the identification of reliable markers of disease severity is essential for risk stratification, prognosis, and individualized management.
Objective: The main objective of this systematic review was to identify and critically appraise validated clinical, laboratory, imaging, and composite markers of severity across major chronic systemic diseases, with secondary objectives focused on prognostic value, clinical applicability, and implications for multidisciplinary care.
Methods: A systematic search was conducted in PubMed, Scopus, Web of Science, Cochrane Library, LILACS, ClinicalTrials.gov, and ICTRP, including studies published in the last five years that evaluated severity markers in chronic systemic diseases, followed by structured data extraction and qualitative synthesis.
Results and Discussion: A total of 20 studies met the inclusion criteria, encompassing cardiovascular, metabolic, inflammatory, renal, respiratory, and autoimmune diseases, and demonstrated heterogeneous but clinically relevant markers associated with disease progression, complications, and mortality.
Conclusion: The findings highlight the growing role of integrated severity markers in guiding clinical decision-making and emphasize the need for standardized, evidence-based approaches to severity assessment in chronic systemic diseases.
Downloads
References
1 Agca, R., Heslinga, S. C., Rollefstad, S., & et al. (2021). EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 80(1), 36–48.
2 Anand, I. S., Claggett, B., Liu, J., & et al. (2023). Interaction between multimarker risk scores and outcomes in heart failure. Journal of the American College of Cardiology, 81(4), 371–382.
3 Cheung, K. L., & Lafayette, R. A. (2020). Renal physiology of pregnancy. Advances in Chronic Kidney Disease, 27(2), 65–71.
4 Cieza, A., Causey, K., Kamenov, K., & et al. (2021). Global estimates of the need for rehabilitation based on the Global Burden of Disease study. The Lancet, 396(10267), 2006–2017.
5 D’Agostino, R. B., Sr., Vasan, R. S., Pencina, M. J., & et al. (2022). General cardiovascular risk profile for use in primary care. Circulation, 145(10), 720–729.
6 Dweck, M. R., Joshi, S., Murigu, T., & et al. (2020). Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. Journal of the American College of Cardiology, 76(23), 2714–2726.
7 Fabbri, E., An, Y., Zoli, M., & et al. (2020). Aging and the burden of multimorbidity: Associations with inflammatory and clinical markers. The Journals of Gerontology: Series A, Biological Sciences and Medical Sciences, 75(11), 2091–2098.
8 Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., & et al. (2021). Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. The Lancet, 398(10302), 786–798.
9 GBD 2019 Diseases and Injuries Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis. The Lancet, 396(10258), 1204–1222.
10 Gheith, O., Al-Otaibi, T., Nampoory, M. R. N., & et al. (2023). Noninvasive fibrosis scores as predictors of outcomes in chronic liver disease. Hepatology, 77(3), 1012–1024.
11 Global Burden of Disease Chronic Diseases Collaborators. (2024). Severity-weighted estimates of chronic disease outcomes worldwide. The Lancet Global Health, 12(3), e421–e432.
12 Huang, C., Wang, Y., Li, X., & et al. (2022). Clinical features and outcomes of patients with chronic obstructive pulmonary disease. The Lancet Respiratory Medicine, 10(1), 43–55.
13 Koppe, L., Fouque, D., & Kalantar-Zadeh, K. (2022). Kidney disease, inflammation, and mineral metabolism. Nature Reviews Nephrology, 18(4), 257–273.
14 Krittanawong, C., Virk, H. U. H., Bangalore, S., & et al. (2024). Inflammatory and imaging biomarkers for risk stratification in chronic coronary syndrome. European Heart Journal, 45(6), 489–498.
15 Li, X., Mayes, M. D., Highland, K. B., & et al. (2024). Organ involvement and survival in systemic sclerosis. Annals of the Rheumatic Diseases, 83(2), 241–248.
16 Marques, C. D. L., Dantas, A. T., Gonçalves, S. M., & et al. (2022). Damage indices and long-term outcomes in systemic lupus erythematosus. Rheumatology (Oxford), 61(9), 3601–3610.
17 Matsue, Y., Kamiya, K., Saito, H., & et al. (2022). Prognostic value of congestion biomarkers in chronic heart failure. Journal of the American College of Cardiology, 79(22), 2141–2153.
18 Matsushita, K., Jassal, S. K., Sang, Y., & et al. (2021). Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults. European Heart Journal, 42(19), 1846–1857.
19 Pencina, M. J., D’Agostino, R. B., Sr., Larson, M. G., & et al. (2020). Predicting the 30-year risk of cardiovascular disease. Circulation, 141(12), 1007–1017.
20 Petersen, S. E., Friedrich, M. G., Leiner, T., & et al. (2021). Cardiovascular magnetic resonance for patients with cardiovascular disease. European Heart Journal, 42(30), 2933–2936.
21 Rapsomaniki, E., Timmis, A., George, J., & et al. (2021). Blood glucose variability and risk of complications in type 2 diabetes. Diabetes Care, 44(4), 905–912.
22 Ridker, P. M. (2021). Residual inflammatory risk: Addressing the obverse side of the atherosclerosis prevention coin. European Heart Journal, 42(15), 1484–1486.
23 Ridker, P. M., Everett, B. M., Thuren, T., & et al. (2021). Antiinflammatory therapy with canakinumab for atherosclerotic disease. The New England Journal of Medicine, 384(7), 661–672.
24 Sattar, N., & McGuire, D. K. (2021). Pathways to cardiorenal disease in diabetes. The New England Journal of Medicine, 385(19), 1767–1770.
25 Topol, E. J. (2020). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 26(1), 44–56.
26 Visseren, F. L. J., Mach, F., Smulders, Y. M., & et al. (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 42(34), 3227–3337.
